Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

189
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
189
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

154
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
154
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

177
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
177
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

144
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
144
Liver Physiology01:30

Liver Physiology

3.4K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.4K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

163
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
163

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency-specific photobiomodulation at theta and gamma enhances cognitive networks and mitigates age-related decline.

GeroScience·2026
Same author

Gender differences in post-traumatic symptomatology among refugees: a systematic review and meta-analysis.

European journal of psychotraumatology·2025
Same author

Neuropsychological Diagnostic Tools in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

Aging and disease·2025
Same author

Impact of body-positive social media content on body image perception.

Journal of eating disorders·2025
Same author

The Differential Effects of Genetic Mutations in ALS and FTD Genes on Behavioural and Cognitive Changes: A Systematic Review and Meta-Analysis.

International journal of molecular sciences·2025
Same author

Transabdominal photobiomodulation applications: A systematic review and meta-analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2025

Related Experiment Video

Updated: Jan 6, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.9K

Metabolism in Acute-On-Chronic Liver Failure: The Solution More than the Problem.

Maria-Angeles Aller1, Natalia Arias2, Javier Blanco-Rivero3

  • 1Department of Surgery, School of Medicine, Complutense University of Madrid, Madrid, Spain.

Archives of Medical Research
|October 9, 2019
PubMed
Summary

Acute-on-chronic liver inflammation involves metabolic changes and organ dysfunction. Mast cells may play a survival role by modulating metabolism during liver failure.

Keywords:
Acute-on-chronicBiliary fibrosisCholestasisInflammationLiver failureMast cellsMetabolismMicrosomal enzymes

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.3K
Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases
06:21

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases

Published on: October 6, 2023

2.5K

Related Experiment Videos

Last Updated: Jan 6, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.9K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.3K
Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases
06:21

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases

Published on: October 6, 2023

2.5K

Area of Science:

  • Hepatology
  • Immunology
  • Metabolic research

Background:

  • Acute-on-chronic liver inflammation involves metabolic impairments and multiorgan dysfunction.
  • Experimental cholestasis models are crucial for studying liver dysfunction and inflammatory responses.

Purpose of the Study:

  • To investigate the role of mast cells in acute-on-chronic liver insufficiency.
  • To explore mast cell involvement in metabolic regulation during liver decompensation.

Main Methods:

  • Utilizing an experimental cholestasis model in rats.
  • Analyzing metabolic changes and inflammatory cytokine profiles.
  • Investigating mast cell infiltration and their potential metabolic functions.

Main Results:

  • Rats in the cholestasis model developed biliary fibrosis and acute-on-chronic decompensation.
  • Acute decompensation was linked to encephalopathy, ascites, renal failure, and increased inflammatory cytokines.
  • Splanchnic mast cell infiltration suggests a compensatory metabolic role, potentially modulating mitochondrial-peroxisome crosstalk.

Conclusions:

  • Mastocytosis in acute-on-chronic hepatic insufficiency may represent a survival mechanism to mitigate liver dysfunction.
  • Understanding mast cell pathophysiology in liver disease could reveal new therapeutic targets.
  • Further research into mast cells' role in liver insufficiency and portal hypertension is warranted.